With anti-programmed cell death protein-1 therapy, inhibition of the immunological rejection-associated neo-oncogene NME4 in LUAD enhanced CD8+ T cell activity and abundance and supported in vivo anti-tumor immunity (Zhang et al., 2024). The gene discussed is CD8A; the disease is neoplasm.